Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study
Influenza and Other Respiratory Viruses2022Vol. 17(1), pp. e13069–e13069
Citations Over TimeTop 10% of 2022 papers
Esther Kissling, Francisco Pozo, Iván Martínez‐Baz, Silke Buda, Ana‐Maria Vilcu, Lisa Domegan, Clara Mazagatos, Frederika Dijkstra, Neus Latorre‐Margalef, Sanja Filipović, Ausenda Machado, Mihaela Lazăr, Itziar Casado, Ralf Dürrwald, Sylvie van der Werf, Joan O’Donnell, Juan Antonio Linares Dopido, Adam Meijer, Maximilian Rieß, Vesna Višekruna Vučina, Ana Paula Rodrigues, Maria Elena Mihai, Jesús Castilla, Luise Goerlitz, Alessandra Falchi, Jeff Connell, Daniel Castrillejo, Mariëtte Hooiveld, AnnaSara Carnahan, Maja Ilić, Raquel Guiomar, Alina Elena Ivanciuc, Marine Maurel, Ajibola Omokanye, Marta Valenciano, I‐MOVE study team
Abstract
Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza.
Related Papers
- → Identification of Novel and Efficacious Chemical Compounds that Disturb Influenza A Virus Entry in vitro(2017)53 cited
- → Factors associated with influenza vaccination in Japanese elderly outpatients(2019)24 cited
- → Rapid Semiautomated Subtyping of Influenza Virus Species during the 2009 Swine Origin Influenza A H1N1 Virus Epidemic in Milwaukee, Wisconsin(2009)39 cited
- → Influenza Vaccination Beliefs and Practices in Elderly Primary Care Patients(2017)15 cited
- → Antibody Response to a Single Injection of Influenza Vaccine among Geriatric Inpatients Vaccinated Annually(1998)2 cited